Chargement en cours...
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor
Background CLR457 is an orally bioavailable pan-phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor. Methods CLR457 anti-tumor activity and pharmacokinetics (PK) were characterized by in vitro biochemical assays and in vivo tumor xenografts. A first-in-human study was conducted to determ...
Enregistré dans:
| Publié dans: | Invest New Drugs |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer US
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6440935/ https://ncbi.nlm.nih.gov/pubmed/30073466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0627-4 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|